Colorectal, biliary tract, pancreatic, and lung carcinomas are similar with respect to their levels of EGFR expression and EGFR signaling; however, a combined inhibition of EGFR and BRAF is accepted mainly for colorectal malignancies, while the remaining cancer types are treated by BRAF and MEK antagonists. This evidence concerns the gene MAP2K7 and cancer.